Spectacle Adherence Among Four-Year-Old Children in the Infant Aphakia Treatment Study

Scott R Lambert1, Lindreth DuBois2, George Cotsonis3

  • 1Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA.

Insights

High spectacle adherence is possible in young children post-cataract surgery. However, children with poorer vision in their treated eye showed the lowest adherence, despite needing eye protection most.

Area of Science:

  • Ophthalmology
  • Pediatric ophthalmology
  • Clinical research

Background:

  • Unilateral cataract surgery in infancy requires effective visual rehabilitation.
  • Spectacle wear is crucial for visual development and protection in children.
  • Assessing adherence to spectacle correction is vital for treatment success.

Purpose of the Study:

  • To evaluate spectacle adherence with impact-resistant lenses in 4-year-old children following unilateral cataract surgery.
  • To identify factors influencing spectacle adherence in this pediatric population.

Main Methods:

  • Retrospective cohort analysis of data from the Infant Aphakia Treatment Study.
  • Involved 114 children randomized to contact lens or intraocular lens correction.
  • Spectacle adherence assessed via diaries and interviews up to age 5 years.

Main Results:

  • Children with better vision (20/40 or better) in the treated eye were more likely to achieve high spectacle adherence (≥80% wear).
  • Spectacle adherence correlated positively with patching adherence.
  • No correlation found between adherence and sex, insurance type, or refractive error.

Conclusions:

  • High spectacle adherence can be achieved in young children after unilateral cataract surgery.
  • Children with poorer vision in the treated eye exhibited the lowest adherence rates.
  • Targeted interventions may be needed for children with suboptimal vision to improve adherence and eye protection.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
293
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
994
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
946
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K